Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 2, 2008, Pages 174-179

  Suryanto, A A ^a   Van Den Broek, J ^b   Hatta, M ^c   De Soldenhoff, R ^d   Van Der Werf, M J ^a,e  

^a Provincial Health Services   (Indonesia)

^b KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^c HASANUDDIN UNIVERSITY   (Indonesia)

^d Netherlands Leprosy Relief ^*  (Indonesia)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Four drug fdc; Indonesia; Relapse; Treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEALTH CENTER; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SPUTUM CULTURE; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDONESIA; MALE; RECURRENCE; TUBERCULOSIS, PULMONARY;

EID: 38949142984     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. WHO/HTM/TB/2006.362. Geneva, Switzerland: WHO, 2006.
2. Menzies R, Rocher I, Vissandjee B. Factors associated with compliance in treatment of tuberculosis. Tuber Lung Dis 1993; 74: 32-37.
3. Demissie M, Kebede D. Defaulting from tuberculosis treatment at the Addis Ababa Tuberculosis Centre and factors associated with it. Ethiop Med J 1994; 32: 97-106.
4. Tekle B, Mariam D H, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. Int J Tuberc Lung Dis 2002; 6: 573-579.
5. Hill P C, Stevens W, Hill S, et al. Risk factors for defaulting from tuberculosis treatment: a prospective cohort study of 301 cases in the Gambia. Int J Tuberc Lung Dis 2005; 9: 1349-1354.
6. Duncan K, Barry C E III. Prospects for new anti-tubercular drugs. Curr Opin Microbiol 2004; 7: 460-465.
7. Gravendeel J M, Asapa A S, Becx-Bleumink M, Vrakking H A. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb) 2003; 83: 183-186.
8. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
9. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79: 61-68.
10. Peloquin C A, Berning S E, Huitt G A, Iseman M D. AIDS and TB drug absorption. Int J Tuberc Lung Dis 1999; 3: 1143-1144.
11. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am Rev Respir Dis 1991; 143: 707-712.
12. Teo S K. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report. Int J Tuberc Lung Dis 1999; 3: 126-132.
13. World Health Organization. Operational guide for National Tuberculosis Control Programmes on the introduction and use of fixed-dose combination drugs. WHO/CDS/TB/2002.308. Geneva, Switzerland: WHO, 2002.
14. McLarty D. Policy implications of adult morbidity and mortality. A preliminary report. Dar es Salaam, Tanzania: University of Dar es Salaam, 1993.
15. van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 1998; 2: 547-552.
16. Pio A, Chaulet P. Tuberculosis handbook. WHO/TB/98.253. Geneva, Switzerland: World Health Organization, 1998.
17. Surveillance WIGPoA-TDR. Anti-tuberculosis drug resistance in the world: third report, 1999-2002. WHO/HTM/TB/2004. 343. Geneva, Switzerland: World Health Organization, 2004.
18. Korenromp E L, Scano F, Williams B G, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003; 37: 101-112.
19. Lambert M L, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-287.
20. Johnson J L, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. UgandaCase Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2000; 4: 1032-1040.
21. Cauthen G M, Pio A, ten Dam H G. Annual risk of tuberculous infection. 1988. Bull World Health Organ 2002; 80: 503-511; Discussion 1-2.
22. Soemantri S, Senewe F P, Tjandrarini D H, et al. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis 2007; 11: 398-404.
23. Verver S, Warren R M, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435.
24. Sonnenberg P, Murray J, Glynn J R, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693.
25. Malkin J E, Prazuck T, Simonnet F, et al. Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis 1997; 1: 68-74.
26. Connolly C, Davies G R, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998; 2: 919-925.
27. Churchyard G J, Kleinschmidt I, Corbett E L, Murray J, Smit J, De Cock K M. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4: 705-712.